TMO Today - Aug 12: FDA news and insider selling
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
TMO Today - Aug 12: FDA news and insider selling
-
ナレーター：
-
著者：
So, what happened? The stock got hit with a small drop, losing a bit of its value. Not a huge shakeup, but still, nobody likes to see their stocks go down, right? The volume was pretty standard, so it wasn’t like a panic sell-off or anything wild.
Now, why did this happen? Well, there’s a mix of stuff going on. First off, there was some chatter about a new FDA-cleared platform for treating multiple myeloma. Sounds fancy, right? But it seems like investors are still trying to process what that actually means for the company long-term. Mixed reactions are always a thing in the market, and this one’s no exception.
On top of that, we had some insider selling today. The VP of Thermo Fisher sold around $245K worth of stock, and the CEO also exercised some options and sold almost 5,000 shares. It’s like, when the big dogs are cashing in, it raises a few eyebrows. People might think, “Do they know something we don’t?” It’s not always a bad sign, but it definitely makes folks a bit uneasy.
Also, on the buying side, Hudson Value Partners and Northside Capital Management both made moves to grab more shares of TMO. So, it’s not all doom and gloom—there’s still interest in the stock.
Looking ahead, it’s worth keeping an eye on how that FDA news plays out. If the new platform gains traction, it could turn things around. But for now, it’s a bit of a waiting game.
Alright, that’s the scoop on TMO today. Just remember, I’m here to share info and keep it real—not giving any financial advice. Catch you later!
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません